Comparison of predictive ability of lipoprotein components to that of traditional risk factors of coronary events in renal transplant recipients

Atherosclerosis

Volumn 208, Issue 1, 2010, Pages 234-239

  Holme, Ingar ^a   Fellstrom, Bengt ^b   Jardine, Alan ^c   Holdaas, Hallvard ^d  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c WESTERN INFIRMARY   (United Kingdom)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Cardiovascular disease; Lipoproteins; Randomised controlled trial; Renal transplantation; Risk factors

Indexed keywords

C REACTIVE PROTEIN; CREATININE; FLUINDOSTATIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; BODY MASS; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; FEMALE; GRAFT RECIPIENT; HUMAN; HYPERTENSION; INFLAMMATION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PATIENT SELECTION; POPULATION RESEARCH; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REFERENCE VALUE; RISK REDUCTION; SURGICAL RISK;

ADULT; AGED; CORONARY ARTERY DISEASE; FEMALE; HUMANS; KIDNEY TRANSPLANTATION; LIPOPROTEINS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PREDICTIVE VALUE OF TESTS; RISK FACTORS;

EID: 73649091144     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2009.06.020     Document Type: Article

References (21)

1. Ojo A.O., Hanson J.A., Wolfe R.A., Leichtman A.B., Agodoa L.Y., and Port F.K. Long-term survival in renal transplant recipients with graft function. Kidney Int. 57 (2000) 307-313
2. Kasiske B.L., Guijarro C., Massy Z.A., Wiederkehr M.R., and Ma J.Z. Cardiovascular disease after renal transplantation. J. Am. Soc. Nephrol. 7 (1996) 158-165
3. Kasiske B.L., Chakkera H.A., and Roel J. Explained and unexplained ischemic heart disease risk after renal transplantation. J. Am. Soc. Nephrol. 11 (2000) 1735-1743
4. Weiner D.E., Tighiouart H., Elsayed E.F., et al. The Framingham predictive instrument in chronic kidney disease. J. Am. Coll. Cardiol. 50 (2007) 217-224
5. Fellstrom B., Jardine A.G., Soveri I., et al. Renal dysfunction as a risk factor for mortality and cardiovascular disease in renal transplantation: experience from the Assessment of Lescol in Renal Transplantation trial. Transplantation 79 (2005) 1160-1163
6. Liu J., Sempos C.T., Donahue R.P., Dorn J., Trevisan M., and Grundy S.M. Non-high-density lipoprotein and very-low-density lipoprotein cholesterol and their risk predictive values in coronary heart disease. Am. J. Cardiol. 98 (2006) 1363-1368
7. Gotto Jr. A.M., Whitney E., Stein E.A., et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the air force/texas coronary atherosclerosis prevention study (AFCAPS/TexCAPS). Circulation 101 (2000) 477-484
8. Simes R.J., Marschner I.C., Hunt D., et al. Relationship between lipid levels and clinical outcomes in the Long-term Intervention with pravastatin in Ischemic disease (LIPID) Trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels?. Circulation 105 (2002) 1162-1169
9. Holdaas H., Fellstrom B., Holme I., et al. Effects of fluvastatin on cardiac events in renal transplant patients: ALERT (Assessment of Lescol in Renal Transplantation) study design and baseline data. J. Cardiovasc. Risk 8 (2001) 63-71
10. Holdaas H., Fellstrom B., Jardine A.G., et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 361 (2003) 2024-2031
11. Holdaas H., Fellstrom B., Cole E., et al. Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study. Am. J. Transplant. 5 (2005) 2929-2936
12. Jardine A.G., Holdaas H., Fellstrom B., et al. fluvastatin prevents cardiac death and myocardial infarction in renal transplant recipients: post-hoc subgroup analyses of the ALERT Study. Am. J. Transplant. 4 (2004) 988-995
13. Ingelsson E., Schaefer E.J., Contois J.H., et al. Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. JAMA 298 (2007) 776-785
14. Pencina M.J., D'Agostino Sr. R.B., D'Agostino Jr. R.B., and Vasan R.S. Evaluating the added prediction ability of a new markeer: from area under the ROC curve to reclassification and beyond. Stat. Med. 27 (2008) 157-172
15. Holme I., Cater N.B., Faergeman O., et al. Lipoprotein predictors of cardiovascular events in statin-treated patients with coronary heart disease. Insights from the Incremental Decrease in End-points through Aggressive Lipid-lowering Trial (IDEAL). Ann. Med. (2008) 1-9
16. Kastelein J.J., van der Steeg W.A., Holme I., et al. Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation 117 (2008) 3002-3009
17. Ong C.S., Pollock C.A., Caterson R.J., Mahony J.F., Waugh D.A., and Ibels L.S. Hyperlipidemia in renal transplant recipients: natural history and response to treatment. Medicine (Baltimore) 73 (1994) 215-223
18. Massy Z.A., Mamzer-Bruneel M.F., Chevalier A., et al. Carotid atherosclerosis in renal transplant recipients. Nephrol. Dial. Transplant. 13 (1998) 1792-1798
19. Barter P., Gotto A.M., LaRosa J.C., et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N. Engl. J. Med. 357 (2007) 1301-1310
20. Holme I., Aastveit A.H., Jungner I., and Walldius G. Relationships between lipoprotein components and risk of myocardial infarction: age, gender and short versus longer follow-up periods in the Apolipoprotein MOrtality RISk study (AMORIS). J. Intern. Med. 264 (2008) 30-38
21. Holdaas H. Preventing cardiovascular outcome in patients with renal impairment: is there a role for lipid-lowering therapy?. Am. J. Cardiovasc. Drugs 5 (2005) 255-269